DelveInsight's "Acute Kidney Injury–Market Insights, Epidemiology and Market Forecast–2034” report delivers an in-depth understanding of the Acute Kidney Injury, historical and forecasted epidemiology as well as the Acute Kidney Injury market trends in the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan.
Acute Kidney Injury market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Acute Kidney Injury market size from 2020 to 2034. The report also covers current Acute Kidney Injury treatment practices/algorithms, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Acute Kidney Injury (AKI) Overview
Acute Kidney Injury (AKI) is characterized by a sudden decline in kidney function, typically evidenced by a rapid increase in nitrogen waste products, such as blood urea nitrogen (BUN) and serum creatinine levels, occurring over hours to weeks. Symptoms of AKI can include nausea, vomiting, weakness, dizziness, and lower back pain. However, some patients may be asymptomatic, while others may experience generalized symptoms not specific to the kidneys.
A thorough medical history and physical examination are crucial for determining the underlying cause of AKI. The medical history can reveal nephrotoxic medications or systemic illnesses contributing to kidney dysfunction. During the physical exam, attention should be given to assessing intravascular volume status. Skin rashes might suggest underlying conditions, such as systemic lupus erythematosus or vasculitis, or exposure to certain drugs that could indicate acute interstitial nephritis. AKI diagnosis is traditionally based on elevated serum creatinine levels and/or reduced urine output. Laboratory tests for diagnosis include serum creatinine measurement, urinalysis, renal biopsy, and urine electrolyte analysis.
Treatment strategies for AKI, as outlined by KDIGO guidelines and care bundles, are primarily supportive. The clinical approach should focus on hemodynamic stabilization, early detection of complications, and addressing the underlying cause of AKI. Hemodynamic stabilization is crucial due to impaired autoregulation in AKI. Treatment depends on the specific cause of the condition. Most patients require hospitalization until kidney function improves. In addition to temporary hemodialysis, treatments may include medications to manage blood levels of vitamins and minerals, and interventions to regulate fluid balance. Currently, there are no approved treatments specifically for AKI; management typically involves conventional therapies (such as vasopressors, diuretics, and statins) and renal replacement therapies (RRT).
Recent updates in the Acute Kidney Injury Market:
-
CalciMedica Announces FDA Clearance of IND Application for Phase 2 Trial of Auxora™ for the Treatment of Severe Acute Kidney Injury
-
US FDA approves Jardiance® for the treatment of adults with chronic kidney disease
Key Highlights from the Acute Kidney Injury (AKI) Market Report:
-
Currently, there are no targeted pharmacotherapies approved for the treatment of Acute Kidney Injury. At present, the therapeutic market size of Acute Kidney Injury is mainly dominated by the use of RRT and off-label drugs, which include various classes such as ACE inhibitors, ARBs, Diuretics, and NSAIDs.
-
Total mortality-adjusted incident cases of Acute Kidney Injury in hospitalized patients in the 7MM accounted for approximately 14.6 million in 2022.
-
In 2022, the market size of Acute Kidney Injury was highest in the United States among the 7MM, accounting for approximately USD 65% million, which is further expected to increase by 2032.
-
In December 2023, SeaStar Medical announced enrollment of patients in the NEUTRALIZE-Acute Kidney Injury pivotal clinical trial of its cell-directed Selective Cytopheretic Device (SCD) extracorporeal therapy in critically ill adults with Acute Kidney Injury requiring continuous kidney replacement therapy (CKRT).
-
In October 2023, Renibus Therapeutics announced that the first patient had been dosed in the pivotal Phase III PROTECT trial of RBT-1 for patients with post-operative complications in cardiac surgery. Top-line results are expected in mid-2025. NDA filing is anticipated by early 2026.
Acute Kidney Injury (AKI) Market
The Acute Kidney Injury (AKI) market is significantly influenced by a promising pipeline of novel therapies and the rising incidence of the condition. The evolving pipeline, featuring innovative mechanisms of action, is poised to transform the market dynamics, which currently rely heavily on biologics and conventional molecules with established mechanisms.
Presently, there are no targeted pharmacotherapies approved specifically for AKI. The market is predominantly driven by renal replacement therapy (RRT) and off-label drugs, including ACE inhibitors, ARBs, diuretics, and NSAIDs.
Comorbidities such as cardiovascular disease, hypertension, diabetes mellitus, chronic kidney disease (CKD), and complications like renal recovery further increase the risk of AKI in affected patients. Currently, the AKI market is largely dependent on RRT and traditional therapies like NSAIDs, ACE inhibitors, ARBs, and diuretics. However, this landscape is expected to shift with the introduction of emerging therapies targeting AKI caused by conditions such as sepsis, cardiac surgery, and delayed graft function.
The AKI pipeline features novel candidates aimed at conditions such as hepatorenal syndrome (HRS)-associated AKI, post-cardiac surgery AKI, and sepsis-related AKI. These developments are set to diversify treatment options and address the current unmet needs in AKI management. Key players in the emerging pipeline include Renibus Therapeutics (RBT-1), Ocelot Bio (OCE-205), AM-Pharma (Ilofotase alfa), and Guard Therapeutics (RMC-035), among others. These companies are working to introduce new therapies that could significantly impact patient outcomes and reduce mortality rates in hospital settings. As a result, the AKI therapeutics market is anticipated to experience substantial growth during the forecast period (2024–2034).
Acute Kidney Injury (AKI) Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders.
-
The total Mortality-adjusted Incident Cases of Acute Kidney Injury in the 7MM comprised 14.6 million cases in 2022 and are projected to increase during the forecast period.
-
The total Mortality-adjusted Incident Cases of Acute Kidney Injury in the United States were approximately 5.7 in 2022.
-
The US contributed to the largest incident population of Acute Kidney Injury, accounting for ~ 39% in the 7MM in 2022.
-
Among EU4 and the UK, Germany accounted for the highest number of Acute Kidney Injury cases, followed by France, whereas Spain accounted for the lowest cases in 2022.
-
The stage-specific cases of Acute Kidney Injury include Stage I, Stage II, and, Stage III. Out of which maximum cases were reported in stage I Acute Kidney Injury followed by stage II and Stage III.
Acute Kidney Injury (AKI) Emerging Drugs
-
RBT-1: Renibus Therapeutics
-
OCE-205: Ocelot Bio
Learn How the Acute Kidney Injury Market Will Evolve and Grow by 2034 @ https://www.delveinsight.com/sample-request/acute-kidney-injury-aki-market
Leading Companies in the Acute Kidney Injury (AKI) Therapeutics Market are Alloksys Life Sciences, AM-Pharma Holding, Ampio Pharmaceuticals Inc., Angion Biomedica, Arch Biopartners Inc., Atorvia, CalciMedica Inc., EBI Exponential Biotherapies, Exponential Biotherapies, Guard Therapeutics, ILIAS Biologics Inc., MediBeacon, Metro International Biotech, LLC, Mission Therapeutics, Ocelot Bio, Inc, Pharming Technologies B.V., Quark-Pharmaceuticals, Rénibus Therapeutics, Sentien Biotechnologies, Serpin Pharma, Sulfateq BV, Vifor Pharma, XORTX Therapeutics, and others.
Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @ https://www.delveinsight.com/sample-request/acute-kidney-injury-aki-market
Table of Contents
1. Key Insights
2. Executive Summary
3. Acute Kidney Injury Competitive Intelligence Analysis
4. Acute Kidney Injury Market Overview at a Glance
5. Acute Kidney Injury Disease Background and Overview
6. Acute Kidney Injury Patient Journey
7. Acute Kidney Injury Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Acute Kidney Injury Treatment Algorithm, Current Treatment, and Medical Practices
9. Acute Kidney Injury Unmet Needs
10. Key Endpoints of Acute Kidney Injury Treatment
11. Acute Kidney Injury Marketed Products
12. Acute Kidney Injury Emerging Drugs and Latest Therapeutic Advances
13. Acute Kidney Injury Seven Major Market Analysis
14. Attribute Analysis
15. Acute Kidney Injury Market Outlook (In US, EU5, and Japan)
16. Acute Kidney Injury Access and Reimbursement Overview
17. KOL Views on the Acute Kidney Injury Market
18. Acute Kidney Injury Market Drivers
19. Acute Kidney Injury Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
Trending reports by DelveInsight:
Adalimumab Biosimilar Market | Arbovirus Infection Market | Artificial Pancreas Device System Market | Dental Equipment Market | Gluten Sensitivity Market | Hypothyroidism Market | Inflammatory Bowel Disease Market | Mayus Kinase Jak Inhibitors Market | Mild Dry Eye Market | Mucopolysaccharidosis Market | Oncolytic Virus Cancer Therapy Market | Pyoderma Gangrenosum Market | Transdermal Drug Delivery Devices Market
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
